18F-Fluorodeoxyglucose Uptake in Cerebrospinal Fluid Reflects Both Brain Glucose Demand and Impaired Blood–Brain Barrier Transport in Alzheimer’s Disease
Source abstract
Abstract
Glucose delivery to the brain requires transporters at the blood–brain barrier (BBB), whose downregulation may be associated with neuronal deficits in Alzheimer’s disease (AD). Whether this downregulation is due to reduced demand or primary BBB dysfunction remains unclear. We investigated novel 18F-Fluorodeoxyglucose Positron Emission Tomography (18F-FDG-PET) measures, namely ventricles (FDGVentricles) and cortical uptake (FDGCortex), and the FDGVentricles/FDGCortex ratio in 224 patients with AD compared to those in 35 controls (CTRLs). AD patients showed lower FDGCortex and FDGVentricles and higher cerebrospinal fluid (CSF) lactates than CTRLs. We found a positive correlation between FDGCortex and FDGVentricles in both groups, although this was less strong in AD patients (AD: r = 0.358; p < 0.001; CTRL: r = 0.516; p = 0.003). Multivariate regression analyses showed that only older age was associated with reduced FDGCortex and FDGVentricles in CTRLs. Conversely, lower FDGCortex was associated with higher Qalb and higher plasma glucose levels within the AD group. Moreover, lower FDGVentricles and FDGVentricles/FDGCortex ratios were associated with elevated CSF lactates in this group. Stratifying AD patients by Apolipoprotein E (APOE) genotype revealed distinct patterns. In APOE ε3 homozygotes, FDGCortex showed no associations, while FDGVentricles and FDGVentricles/FDGCortex were negatively associated with CSF lactate. In APOE ε4 carriers, lower FDGCortex was linked to higher plasma glucose and QAlb, whereas FDGVentricles and FDGVentricles/FDGCortex were positively associated with CSF p-tau/Aβ42. Our findings suggest that, in patients with AD, FDGVentricles and the FDGVentricles/FDGCortex ratio may reflect alterations in brain metabolism and glucose extraction capacity. These parameters are differently linked with age, BBB integrity, and metabolic dysfunction (CSF lactates), according to APOE genotype.
Source: crossref · Quality: baseline
Research context
OpenAlex topics: Neurological and metabolic disorders · Advanced Neuroimaging Techniques and Applications · Lanthanide and Transition Metal Complexes
SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.
Affiliations
Memory Clinic, Policlinico Tor Vergata, University of Rome Tor Vergata, 00133 Rome, Italy
Neurology Unit, Policlinico Tor Vergata, University of Rome Tor Vergata, 00133 Rome, Italy
Department of Biomedicine and Prevention, University of Rome Tor Vergata, 00133 Rome, Italy
IRCCS Neuromed, 86077 Pozzilli, Italy
References (37)
Show source-provided references
1. Vascular Dysfunction-The Disregarded Partner of Alzheimer’s Disease10.1016/j.jalz.2018.07.222 ↗
2. Neurovascular Pathways to Neurodegeneration in Alzheimer’s Disease and Other Disorders10.1038/nrn3114 ↗
3. Cerebral Glucose Metabolism in Alzheimer’s Disease10.1016/j.cortex.2024.07.004 ↗
4. Pre-Clinical Detection of Alzheimer’s Disease Using FDG-PET, with or without Amyloid Imaging10.3233/JAD-2010-091504 ↗
5. The Use of PET in Alzheimer Disease10.1038/nrneurol.2009.217 ↗
6. Reduced Cerebral Glucose Metabolism in Patients at Risk for Alzheimer’s Disease10.1016/j.pscychresns.2006.12.003 ↗
7. Regional Glucose Metabolic Abnormalities Are Not the Result of Atrophy in Alzheimer’s Disease10.1212/WNL.50.6.1585 ↗
8. Glucose Transporters at the Blood-Brain Barrier: Function, Regulation and Gateways for Drug Delivery10.1007/s12035-015-9672-6 ↗
9. GLUT1 Reductions Exacerbate Alzheimer’s Disease Vasculo-Neuronal Dysfunction and Degeneration10.1038/nn.3966 ↗
10. Blood-Brain Barrier-Associated Pericytes Internalize and Clear Aggregated Amyloid-Β42 by LRP1-Dependent Apolipoprotein E Isoform-Specific Mechanism10.1186/s13024-018-0286-0 ↗
11. Reduced Glucose Transporter at the Blood-Brain Barrier and in Cerebral Cortex in Alzheimer Disease10.1111/j.1471-4159.1989.tb07399.x ↗
12. Roles of Facilitative Glucose Transporter GLUT1 in [18F]FDG Positron Emission Tomography (PET) Imaging of Human Diseases10.17229/jdit.2015-0301-014 ↗
13. Zhou, Z., Zhao, T., Gardus, J., Wen, Q., Feng, Y., DeLorenzo, C., Parsey, R., and Huang, C. (2025). Quantifying Ventricular CSF Clearance in the Human Brain Using Dynamic 18F-FDG PET: Insights into Age-Related Glymphatic Impairment. medRxiv.10.1101/2025.04.07.25325241 ↗
14. Shift in Brain Metabolism in Late Onset Alzheimer’s Disease: Implications for Biomarkers and Therapeutic Interventions10.1016/j.mam.2011.10.005 ↗
15. APOE and Alzheimer’s Disease: Advances in Genetics, Pathophysiology, and Therapeutic Approaches10.1016/S1474-4422(20)30412-9 ↗
16. APOE and Metabolic Dysfunction in Alzheimer’s Disease10.1016/bs.irn.2020.02.002 ↗
17. Human ApoE Isoforms Differentially Modulate Brain Glucose and Ketone Body Metabolism: Implications for Alzheimer’s Disease Risk Reduction and Early Intervention10.1523/JNEUROSCI.2262-17.2018 ↗
18. The Diagnosis of Dementia Due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease10.1016/j.jalz.2011.03.005 ↗
19. The Diagnosis of Mild Cognitive Impairment Due to Alzheimer’s Disease: Recommendations from the National Institute on Aging-Alzheimer’s Association Workgroups on Diagnostic Guidelines for Alzheimer’s Disease10.1016/j.jalz.2011.03.008 ↗
20. EANM Procedure Guidelines for Brain PET Imaging Using [18F]FDG, Version 310.1007/s00259-021-05603-w ↗
21. Atlas-to-Image Non-Rigid Registration by Minimization of Conditional Local Entropy
22. A Probabilistic Atlas of the Human Brain: Theory and Rationale for Its Development10.1006/nimg.1995.1012 ↗
23. An Automated Method for Neuroanatomic and Cytoarchitectonic Atlas-Based Interrogation of FMRI Data Sets10.1016/S1053-8119(03)00169-1 ↗
24. The Pons as Reference Region for Intensity Normalization in Semi-Quantitative Analysis of Brain 18FDG PET: Application to Metabolic Changes Related to Ageing in Conventional and Digital Control Databases10.1186/s13550-021-00771-0 ↗
25. Brain [F-18]FDG PET for Clinical Dementia Workup: Differential Diagnosis of Alzheimer’s Disease and Other Types of Dementing Disorders10.1053/j.semnuclmed.2021.01.002 ↗
26. Demetrius, L.A., Magistretti, P.J., and Pellerin, L. (2015). Alzheimer’s Disease: The Amyloid Hypothesis and the Inverse Warburg Effect. Front. Physiol., 5.10.3389/fphys.2014.00522 ↗
27. Evidence Supporting the Existence of an Activity-Dependent Astrocyte-Neuron Lactate Shuttle10.1159/000017324 ↗
28. Peters, A., Sprengell, M., and Kubera, B. (2022). The Principle of “brain Energy on Demand” and Its Predictive Power for Stress, Sleep, Stroke, Obesity and Diabetes. Neurosci. Biobehav. Rev., 141.10.1016/j.neubiorev.2022.104847 ↗
29. The Human Brain GLUT1 Glucose Transporter: Ultrastructural Localization to the Blood-Brain Barrier Endothelia10.1038/jcbfm.1994.15 ↗
30. Ischemic Injury Induces Brain Glucose Transporter Gene Expression10.1210/endo.133.6.8243275 ↗
31. Cellular Mechanisms of Brain Energy Metabolism and Their Relevance to Functional Brain Imaging10.1098/rstb.1999.0471 ↗
32. Cerebrospinal Fluid Lactate Levels and Brain [18F]FDG PET Hypometabolism within the Default Mode Network in Alzheimer’s Disease10.1007/s00259-016-3417-2 ↗
33. Molecular Biology of the Blood-Brain and the Blood-Cerebrospinal Fluid Barriers: Similarities and Differences10.1186/2045-8118-8-3 ↗
34. Is Cerebral Glucose Metabolism Related to Blood-Brain Barrier Dysfunction and Intrathecal IgG Synthesis in Alzheimer Disease? A 18 F-FDG PET/CT Study10.1097/MD.0000000000004206 ↗
35. State of the Science on Brain Insulin Resistance and Cognitive Decline Due to Alzheimer’s Disease
36. Assessment of Neurovascular Uncoupling: APOE Status Is a Key Driver of Early Metabolic and Vascular Dysfunction10.1002/alz.13842 ↗
37. Williams, H.C., Farmer, B.C., Piron, M.A., Walsh, A.E., Bruntz, R.C., Gentry, M.S., Sun, R.C., and Johnson, L.A. (2020). APOE Alters Glucose Flux through Central Carbon Pathways in Astrocytes. Neurobiol. Dis., 136.10.1016/j.nbd.2020.104742 ↗